Discontinuation of disease-modifying treatments for multiple sclerosis in patients aged over 50 with disease Inactivity

Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60

(2018) Le H Hua et al.   Multiple Sclerosis Journal

Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis

(2018) Alexander Rae-Grant et al.   NEUROLOGY

Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60

(2018) Le H Hua et al.   Multiple Sclerosis Journal

Discontinuation of disease modifying treatments in middle aged multiple sclerosis patients. First line drugs vs natalizumab

(2017) Jan Fagius et al.   Multiple Sclerosis and Related Disorders

A Review of Propensity-Score Methods and Their Use in Cardiovascular Research

(2016) Saswata Deb et al.   CANADIAN JOURNAL OF CARDIOLOGY

Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis?

(2016) J. Bonenfant et al.   EUROPEAN JOURNAL OF NEUROLOGY

Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study

(2016) Ilya Kister et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies

(2015) Peter C. Austin et al.   STATISTICS IN MEDICINE

Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort

(2015) Dalia L. Rotstein et al.   JAMA Neurology

From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter Study

(2014) Luca Prosperini et al.   EUROPEAN NEUROLOGY

Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients

(2014) Per Soelberg Sorensen et al.   JOURNAL OF NEUROLOGY

Relapses and disability accumulation in progressive multiple sclerosis

(2014) M. M. Paz Soldan et al.   NEUROLOGY

MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study

(2014) R. J. Fox et al.   NEUROLOGY

Medication withdrawal may be an option for a select group of patients in relapsing-remitting multiple sclerosis

(2013) Guilherme Sciascia do Olival et al.   ARQUIVOS DE NEURO-PSIQUIATRIA

Short-term and long-term safety and tolerability of interferon β-1b in multiple sclerosis

(2013) Anthony T. Reder et al.   Multiple Sclerosis and Related Disorders

Estimating the prevalence and incidence of multiple sclerosis in the Lorraine region, France, by the capture–recapture method

(2012) Haritina El Adssi et al.   Multiple Sclerosis Journal

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

Discontinuation of interferon beta therapy in multiple sclerosis patients with high pre-treatment disease activity leads to prompt return to previous disease activity

(2011) Małgorzata Siger et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

The relation between inflammation and neurodegeneration in multiple sclerosis brains

(2009) Josa M. Frischer et al.   BRAIN

Natural history of multiple sclerosis in a population-based cohort

(2008) M. Debouverie et al.   EUROPEAN JOURNAL OF NEUROLOGY

Relapses in multiple sclerosis are age- and time-dependent

(2008) H Tremlett et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Natural history of secondary-progressive multiple sclerosis

(2008) Helen Tremlett et al.   Multiple Sclerosis Journal